Very Low Vitamin D Levels are a Strong Independent Predictor of Mortality in Hospitalized Patients with Severe COVID-19

摘要

Background. There is controversy regarding the association between hypovitaminosis D and COVID-19 outcomes.Aim of the study. We assessed the association between 25-hydroxyvitamin D levels and COVID-19 outcomes in hospitalized subjects with severe SARS-CoV-2 infection. nbsp;Methods. Retrospective cohort study. Serum 25-hydroxyvitamin D levels of subjects with severe COVID-19 pneumonia were measured at hospital admission, between March 17th, 2020, and March 1st, 2021. nbsp;Results. Out of 2,908 patients, 571 (19.6) had vitamin D deficiency (defined as a serum 25-hydroxyvitamin D level < 12.5 ng/mL < 31.25 nmol/L), and 1069 (36.7) had levels between 12.5 ng/mL (31.25 nmol/L) and 20 ng/mL 850 nmol/L). Compared to subjects without vitamin D deficiency, those with 25-hydroxyvitamin D level < 12.5 ng/mL had higher rates of in-hospital mortality at 30 d (28.0 vs. 17.3; p < 0.001), global mortality (31.9 vs. 20.8; p < 0.001), mechanical ventilation requirement (23.8 vs. 17.2; p < 0.001), and significantly longer hospital stay (median interquartile range of 9 6-17 d vs. 7 5-12 d, p < 0.001). In the unadjusted analysis, the risk of in-hospital death was greater for patients with vitamin D deficiency (HR 1.43; 95 CI, 1.20-1.70; p < 0.001). After adjusting for confounders, the risk of in-hospital death within 30 d remained significantly greater in patients with vitamin D deficiency (HR 1.46; 95 CI, 1.21-1.76; p < 0.001). The risk was reduced but remained significant with 25-hydroxyvitamin D levels between 12.5 ng/mL and 20 ng/mL (HR 1.31; 95 CI 1.10-1.55, p = 0.02). In comparison with other clinical biomarkers, vitamin D deficiency was an independent predictive marker of in-hospital mortality after adjusting for confounders. nbsp;Conclusion. Very low 25-hydroxyvitamin D levels measured at hospital admission were significantly associated with in-hospital mortality and are a useful prognostic biomarker in severe COVID-19 patients. (c) 2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.